开发CDK2选择性的小分子抑制剂...__

开发CDK2选择性的小分子抑制剂...

可下载资源数量

已经购买

下载数量：1

单价	0 1.0
Coupon	100% 0%
Total	0 1.0

点击下载点击购买并下载

点击购买，资源将自动在新窗口打开.

机构名称：

开发CDK2选择性的小分子抑制剂...

¥ 1.0

热度

 Primary resistance: About 15% of patients treated with CDK4/6 inhibitor (CDK4/6i) + aromatase inhibitor, and up to 30% of those treated with CDK4/6i + fulvestrant, will develop recurrent disease within 6 months  Acquired resistance: Almost all patients will eventually develop progressive disease  Multiple pathways are implicated in resistance  CCNE1 amplification and cyclin E1 overexpression are

添加pdf代下载 VIP点击下载文件